Num | PTM | Disease | Cell Type | Type | PTM Site | PMID |
---|
1 | Phosphorylation | Cervical squamous cell cancer | | P | | 23696930 |
[Reference]: Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients |
|
2 | Phosphorylation | Breast cancer/tumor/carcinoma | cell line | P | | 23353055 |
[Reference]: Silencing TRPM7 with RNA interference resulted in a significant decrease in migration and invasion capability of MDA-MB-435 breast cancer cells, and phosphorylation levels of Src and MAPK but not AKT |
|
3 | Phosphorylation | Cervical cancer/carcinoma | | P | | 24058594 |
[Reference]: The overexpression of scaffolding protein NEDD9 promotes migration and invasion in cervical cancer via tyrosine phosphorylated FAK and SRC |
|
4 | Tyrosine Phosphorylation | Breast cancer/tumor/carcinoma | | U | Y215 | 12753909 |
[Reference]: Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. |
|
5 | Tyrosine Phosphorylation | Severe osteopetrosis | tumor tissue | P | Y416 | 23526378 |
[Reference]: The phosphorylation of cellular Rous sarcoma oncogene (c-Src) at Tyr-527 is significantly elevated whereas at Tyr-416 is decreased in Lrrk1-deficient osteoclasts |
|
6 | Tyrosine Phosphorylation | Ovarian cancer/carcinoma | tumor tissue | U | Y416 | 23277333 |
[Reference]: As shown in Table 1, significant differences in c-Src and phospho-Src expression were observed between the groups; a significantly greater proportion of patients in the ovarian cancer group had positive c-Src and phospho-Src expression (P < 0.001) |
|
7 | Tyrosine Phosphorylation | Prostate cancer/carcinoma/adenocarcinoma | cell line | U | Y416 | 23145001 |
[Reference]: In addition, although the expected enhanced phosphorylation of Src at Tyr-416 (activation site) is present in the most aggressive prostate cancer cell lines, unexpectedly high phosphorylation levels at the Tyr-527 inhibitory site are observed as well. |
|
8 | Tyrosine Phosphorylation | Oral squamous cell carcinoma | | D | Y419 | 23707351 |
[Reference]: Decreased phosphorylation of Src, CTTN, and FAK also followed EGCG treatment |
|
9 | Tyrosine Phosphorylation | Barrett's neoplasia | | D | Y419 | 14608530 |
[Reference]: Our data indicate that expression levels of IGF1-R, c-Src, and Bcl-X(L) proteins are coordinately elevated in Barrett's-associated neoplasia. |
|
10 | Tyrosine Phosphorylation | Acute myeloid leukaemia/Acute myelogenous leukemia | | P | Y419 | 18056483 |
[Reference]: A critical role for Lyn in acute myeloid leukemia. |
|
11 | Tyrosine Phosphorylation | Glioblastoma | | P | Y419 | 22323579 |
[Reference]: Finally, phosphorylated Dock180(Y722) is coexpressed with EGFRvIII and phosphorylated Src(Y418) in clinical specimens, and such coexpression correlates with an extremely poor survival in glioblastoma patients. |
|
12 | Tyrosine Phosphorylation | Hepatocellular carcinoma/Hepatocarcinoma/Hepatoma | tumor tissue | P | Y419 | 24296779; 23524339 |
[Reference]: PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2 |
|
13 | Tyrosine Phosphorylation | Gestational choriocarcinoma | JEG-3 cell line | P | Y419 | 23671128 |
[Reference]: Transfection of ASPP2 but not ASPP1, another tumor-suppressive ASPP, was found to be related to subsequent decreased Src-pY416 phosphorylation, suggesting an inactivating effect of ASPP2 on Src |
|
14 | Tyrosine Phosphorylation | Glioma/Adult gliomas | | U | Y419 | 24358106 |
[Reference]: Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. |
|
15 | Tyrosine Phosphorylation | Prostate cancer/carcinoma/adenocarcinoma | | U | Y419 | 17045208 |
[Reference]: Phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones. |
|
16 | Tyrosine Phosphorylation | Breast cancer/tumor/carcinoma | | U | Y419 | 21490376; 24358106; 12753909; 17967179; 26923594 |
[Reference]: the activated form of Src (phosphoY418) was highly detectable in brain tumor extracts, while it was barely detectable in non-tumor brain;HER2(+) breast cancer. Strong pY216, modest pY419.;in selected cell lines;higher in basal subtype BC;TNBC;higher in basal subtype BC;TNBC |
|
17 | Tyrosine Phosphorylation | Colon cancer/carcinoma | | U | Y419 | 17148760 |
[Reference]: We have validated the use of phospho-specific antibodies against Src Tyr(419) and paxillin Tyr(118) as biomarkers of dasatinib activity in vivo. Colon carcinoma-bearing mice treated with dasatinib showed a decrease in both phospho-Src Tyr(419) and phospho-paxillin Tyr(118) in peripheral blood mononuclear cells, which correlated with inhibition of Src activity in the colon tumors.? |
|
18 | Tyrosine Phosphorylation | Severe osteopetrosis | tumor tissue | P | Y527 | 23526378 |
[Reference]: The phosphorylation of cellular Rous sarcoma oncogene (c-Src) at Tyr-527 is significantly elevated whereas at Tyr-416 is decreased in Lrrk1-deficient osteoclasts |
|
19 | Tyrosine Phosphorylation | Hepatocellular carcinoma/Hepatocarcinoma/Hepatoma | | D | Y530 | 24296779 |
[Reference]: Moreover, we also found that the phosphorylation level of negative regulatory site of Src (Y527) was significantly decreased in MPZL1-overexpressing cells |
|
20 | Tyrosine Phosphorylation | Barrett's neoplasia | | D | Y530 | 14608530 |
[Reference]: Our data indicate that expression levels of IGF1-R, c-Src, and Bcl-X(L) proteins are coordinately elevated in Barrett's-associated neoplasia. |
|
21 | Tyrosine Phosphorylation | Colon cancer/carcinoma | | D | Y530 | 23467908 |
[Reference]: Y530 phosphorylation in the carcinomas was greatly reduced as compared to FHC |
|
22 | Tyrosine Phosphorylation | Breast cancer/tumor/carcinoma | tumor tissue | U | Y530 | 21490376 |
[Reference]: High expression of Y416Src was significantly associated with metastatic disease (p=0.0327), whereas high expression of Y527Src was significantly associated with metastatic disease (p=0.0004), clinical stage (p=0.0062), as well as HER2 status (p=0.0149). High expression of either Y416Src or Y527Src was significantly correlated with poor overall survival (p=0.0049 and p<0.0001, respectively). |
|
23 | Tyrosine Phosphorylation | Prostate cancer/carcinoma/adenocarcinoma | cell line | U | Y530 | 23145001 |
[Reference]: In addition, although the expected enhanced phosphorylation of Src at Tyr-416 (activation site) is present in the most aggressive prostate cancer cell lines, unexpectedly high phosphorylation levels at the Tyr-527 inhibitory site are observed as well. |
|